Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates

被引:122
|
作者
Kuipers, ME
de Vries, HG
Eikelboom, MC
Meijer, DKF
Swart, PJ
机构
[1] Univ Groningen, Inst Drug Studies, Univ Ctr Pharm, Sect Pharmacokinet & Drug Delivery, NL-9713 AV Groningen, Netherlands
[2] Univ Groningen Hosp, Sect Med Microbiol, NL-9713 GZ Groningen, Netherlands
关键词
D O I
10.1128/AAC.43.11.2635
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Because of the rising incidence of failures in the treatment of oropharyngeal candidosis in the case of severely immunosuppressed patients (mostly human immunodeficiency virus [HIV]-infected patients), there is need for the development of new, more effective agents and/or compounds that support the activity of the common antifungal agents. Since lactoferrin is one of the nonspecific host defense factors present in saliva that exhibit antifungal activity, we studied the antifungal effects of human, bovine, and iron-depleted lactoferrin in combination with fluconazole, amphotericin B, and 5-fluorocytosine in vitro against clinical isolates of Candida species. Distinct antifungal activities of lactoferrin were observed against clinical isolates of Candida. The MICs generally were determined to be in the range of 0.5 to 100 mg.ml(-1). Interestingly, in the combination experiments we observed pronounced cooperative activity against the growth of Candida by using lactoferrin and the three antifungals tested. Only in a limited concentration range was minor antagonism detected. The use of lactoferrin and fluconazole appeared to be the most successful combination. Significant reductions in the minimal effective concentrations of fluconazole were found when it was combined with a relatively low lactoferrin concentration (1 mg/ml). Such combinations still resulted in complete growth inhibition, while synergy of up to 50% against several Candida species was observed. It is concluded that the combined use of lactoferrin and antifungals against severe infections with Candida is an attractive therapeutic option. Since fluconazole-resistant Candida species have frequently been reported, especially in HIV infected patients, the addition of lactoferrin to the existing fluconazole therapy could postpone the occurrence of species resistance against fluconazole. Clinical studies to further elucidate the potential utility of this combination therapy have been initiated.
引用
收藏
页码:2635 / 2641
页数:7
相关论文
共 50 条
  • [31] Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents
    Wakabayashi, H
    Abe, S
    Okutomi, T
    Tansho, S
    Kawase, K
    Yamaguchi, H
    MICROBIOLOGY AND IMMUNOLOGY, 1996, 40 (11) : 821 - 825
  • [32] Clinical Candida krusei isolates remain susceptible during extensive exposure to antifungal drugs
    Hautala, Timo
    Kakko, Sakari
    Siitonen, Timo
    Saily, Marjaana
    Koistinen, Pirjo
    Koskela, Markku
    MEDICAL MYCOLOGY, 2010, 48 (01) : 79 - 84
  • [33] The synthesis and synergistic antifungal effects of chalcones against drug resistant Candida albicans
    Wang, Yuan-Hua
    Dong, Huai-Huai
    Zhao, Fei
    Wang, Jie
    Yan, Fang
    Jiang, Yuan-Ying
    Jin, Yong-Sheng
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (13) : 3098 - 3102
  • [34] In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei
    Drago, M
    Scaltrito, MM
    Morace, G
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2004, 23 (08) : 619 - 624
  • [35] In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei
    M. Drago
    M. M. Scaltrito
    G. Morace
    European Journal of Clinical Microbiology and Infectious Diseases , 2004, 23 : 619 - 624
  • [36] Antifungal activity of posaconazole against Candida spp. and non-Candida clinical yeasts isolates
    Javier Carrillo-Munoz, Alfonso
    Tur-Tur, Cristina
    Hernandez-Molina, Juan M.
    Quindos, Guillermo
    Marcos-Arias, Cristina
    Eraso, Elena
    Cardenes, Delia
    Ortiz-Maestro, Oscar
    Santos, Patricia
    Estivill, Dolors
    Guardia, Celia
    Giusiano, Gustavo
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2010, 23 (03) : 122 - 125
  • [37] Synergistic Antifungal Activity of Chito-Oligosaccharides and Commercial Antifungals on Biofilms of Clinical Candida Isolates
    Ganan, Monica
    Lorentzen, Silje B.
    Gaustad, Peter
    Sorlie, Morten
    JOURNAL OF FUNGI, 2021, 7 (09)
  • [38] Synergistic Effect of Essential Oils and Antifungal Agents in Fighting Resistant Clinical Isolates of Candida auris
    Cavallo, Lorenza
    Menotti, Francesca
    Roana, Janira
    Costa, Cristina
    Longo, Fabio
    Pagano, Claudia
    Curtoni, Antonio
    Bondi, Alessandro
    Banche, Giuliana
    Allizond, Valeria
    Mandras, Narcisa
    PHARMACEUTICS, 2024, 16 (07)
  • [39] In vitro synergistic efficacy of combination of amphotericin B with Myrtus communis essential oil against clinical isolates of Candida albicans
    Mahboubi, M.
    Bidgoli, F. Ghazian
    PHYTOMEDICINE, 2010, 17 (10) : 771 - 774
  • [40] Antifungal activity of nitroxoline against Candida auris isolates
    Fuchs, Frieder
    Hof, Herbert
    Hofmann, Sandra
    Kurzai, Oliver
    Meis, Jacques F.
    Hamprecht, Axel
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (11) : 1697.e7 - 1697.e10